Showing results (271-280 of 483) with videos related to

Sort By:
Pageof 49
Blood Advances|May 10, 2023
Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR studySaad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 11, 2024
Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion StudyMaria-Victoria Mateos, Katja Weisel, Joris Diels, et al.
Leukemia & Lymphoma|November 9, 2018
A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysisKatja Weisel, Pieter Sonneveld, Andrew Spencer, et al.
Frontiers in Oncology|January 21, 2025
Outcome of critically ill patients receiving systemic chemotherapy on the intensive care unitPanagiotis Karagiannis, Felix Klingler, Viktor Arelin, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 14, 2025
Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR TrialKatja Weisel, Maria-Victoria Mateos, Ola Landgren, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 15, 2026
Malignancy-Associated Hemophagocytic Lymphohistiocytosis: Clinical Characteristics, Treatment Patterns, and Survival Outcomes in a Tertiary Care Center CohortRicardo Kosch, Winfried Alsdorf, Paymon Ahmadi, et al.
Oncology Letters|August 15, 2014
Interleukin 4, interleukin 6 and osteopontin-serological markers of head and neck malignancy in primary diagnostics: A pilot studyChristoph Aderhold, Guido Manuel Grobschmidt, Alexander Sauter, et al.
Life Science Alliance|November 17, 2022
GPER1 links estrogens to centrosome amplification and chromosomal instability in human colon cellsMiriam Bühler, Jeanine Fahrländer, Alexander Sauter, et al.
Frontiers in Medicine|November 25, 2021
Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and MyelomaFranziska Brauneck, Pauline Weimer, Julian Schulze Zur Wiesch, et al.
Annals of Hematology|January 8, 2025
Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodiesLuciano J Costa, Francesca Gay, Ola Landgren, et al.
Pageof 49